Please assess the completion status of the following clinical trial:

Trial Title: University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Autism diagnostic observation schedule (ADOS) score of ≥ 7~* Diagnosis of autism spectrum disorder by Diagnostic and Statistical Manual, 5th edition (DSM-V)~* Stable treatment and diet regimen for ≥ 2 months~* Resident of San Diego region~Exclusion Criteria:~* Any prescription medications~* Hospitalization within the previous 2 months~* Active medical problem such as seizures, heart, liver, kidney, or adrenal disease~* Planning to start a new drug, diet, or behavioral intervention during the study~* Weight under the 5th percentile for age~* Unable to tolerate venipuncture, urine collection, or an indwelling intravenous catheter for 3-4 hours~* Plasma creatinine ≥ 1.4 mg/dl~* Liver function alanine amino transferase (ALT) or aspartate amino transferase (AST) ≥ 1.5-fold above the upper limit of normal~* Known intolerance to suramin or other antipurinergic drugs~* Unable to perform or cooperate with study requirements

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Suramin (Type: ACTIVE_COMPARATOR): 20 mg/kg suramin in 50 ml of saline by intravenous infusion over 30 minutes
- Saline (Type: PLACEBO_COMPARATOR): 50 ml of saline by intravenous infusion over 30 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).